Navigation Links
Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
Date:10/24/2011

NEW YORK, Oct. 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

http://www.reportlinker.com/p0568107/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I- 2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

Summary

GlobalData, the industry analysis specialist, has released its new report, "Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011". The report is an essential source of information and analysis on the global gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global gastric cancer therapeutics market. It analyses the treatment usage patterns in the global gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global gastric cancer sector. It quantifies the unmet need in the global gastric cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The Scope of the report includes:
- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in different regions.
- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the global Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the global gastric cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global gastric cancer therapeutics market till 2020.
- Quantifying patient population in the global gastric cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the global gastric cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What's the next big thing in the global gastric cancer therapeutics market landscape? Identify, understand and capitalize

To order this report:

: Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
2. Gastric Banding Reverses Impact of Type 2 Diabetes
3. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
4. Mayo Clinic Discovery May Help Diabetic Gastric Problem
5. RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
6. FDA Provides 510k Clearance for BARRX Medicals HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE)
7. FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers
8. While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group
9. The Spatz Adjustable Balloon System® for Weight Loss Becomes the First Intragastric Balloon to Receive Regulatory Approval for 1 Year Implantation Time
10. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
11. Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):